Teva Pharmaceutical announced a proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $40 billion Read the full story

Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni Read the full story

Theravance Biopharma and Mylan announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease and other respiratory diseases. Read the full story

Mylan has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women's health care company with global leadership in generic oral contraceptive products for $750 million in cash plus additional contingent payments of up to $50 million. Read the full story

Mylan Laboratories is expanding its hepatitis C licensing agreement with Gilead Sciences to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 Read the full story

Mylan has entered into an agreement with Gilead Sciences under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide Read the full story

Mylan announces the acquistion of the U.S. commercialization, marketing and intellectual property rights of Arixtra. Read the full story

Several companies, including Mylan , have submitted a second round of bidding for a portfolio of older GlaxoSmithKline drugs. Read the full story

Mylan, big pharma, will acquire Abbott's non-U.S. developed markets specialty and branded generics business ("the Assets") in an all-stock transaction. Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story